About US
Contact us
-
Fosun stock tumbles over rumors of chairman disappearance—againFosun Chairman Guo Guangchang is not missing, the Chinese conglomerate said, as it tried to refute online rumors that sent subsidiary Fosun Pharma’s shares down more than 8% in Shanghai Thursday morni2017/7/28
-
Endo caves to FDA pressure, will pull Opana ER from the marketUnder pressure from the FDA, Endo has decided to pull from the market its opioid painkiller Opana ER, a drug that generated nearly $160 million in sales last year. The Dublin-based drugmakersaidthat2017/7/28
-
Forget Sanofi's Zika shot. A new measure would limit pricing on all DOD-funded medicationThe controversy over Sanofi's eventual pricing for an in-development Zika vaccine might just spawn pricing constraints for all treatments developed with the help of Defense Department funding. Under2017/7/27
-
Trial deaths frustrate Merck's bid to pair Keytruda with Celgene's myeloma starsAfter reviewing deaths in two Keytruda trials, the FDA put both Merck studies on clinical hold and stopped Keytruda dosing in a third, thwarting Merck's hopes for combining Keytruda with Celgene's big2017/7/27
-
Amgen, Teva hikes show pharma can't blame rebates for all price increases: analystPharma companies and pharmacy benefit managers have engaged in a back-and-forth for months over who’s to blame for high drug prices. Drugmakers say they're raising prices largely to keep ahead of PBMs2017/7/26
-
With its €5.3B buyout scuppered, Stada brings in new CEO, CFOAfter failing to win the shareholder support needed to complete a €5.32 billion buyout, Stada is changing key executives. The company announced the resignations of CEO Matthias Wiedenfels and CFO Helm2017/7/26
-
Lilly’s Olumiant, spurned by FDA, gets nod from NICEEli Lilly has won a nod from NICE for its anticipated blockbuster and Humira competitor, Olumiant, a modicum of good news for a drug the FDA rejected in April. England’s cost watchdog, in final guida2017/7/25
-
Bayer stops production of Gynera contraceptive in BrazilBrazilian authorities, which earlier ordered drugmaker Bayer to pull its Essure birth control device from the market, have now asked for the recall of more than a dozen lots of a Bayer birth control p2017/7/25
-
As Congress battles over healthcare, Johnson & Johnson CEO says real reform will take time—and cooperationWhile Republican senators work feverishly on a healthcare bill, one prominent pharma CEO says overhauling the system won't take a few weeks of work. Think years, even decades—and he'd like Democrats t2017/7/24
-
Need proof that CV outcomes are make-or-break? See Merck's reaction to anacetrapib trial winFew thought Merck & Co.’s cholesterol-fighting candidate anacetrapib would hit its phase 3 trial goals. After all, three other drugs in the CETP inhibitor class failed dismally. But anacetrapib pu2017/7/24